Last update 21 Nov 2024

Topiramate

Overview

Basic Info

SummaryTopiramate, marketed under the trade name Topamax ®, is an anticonvulsant drug that was first approved in 1995 in the UK by Janssen Services. Its mechanism of action involves acting as a GABAAR agonist. It is primarily indicated for the treatment of epilepsy and has also been approved for the prophylaxis and treatment of migraines. Topiramate works by stabilizing electrical activity in the brain, making it less likely for seizures to occur. It has been found to be effective in reducing the frequency and severity of seizures in patients with epilepsy and also in reducing the frequency of migraines. Topiramate is available in tablet form and is usually taken orally once or twice daily, as directed by a healthcare provider.
Drug Type
Small molecule drug
Synonyms
2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate, 2,3:4,5-di-O-isopropylidene-β-D-fructopyranose sulfamate, TPM
+ [21]
Mechanism
AMPA receptor antagonists(Glutamate receptor ionotropic AMPA antagonists), CAs inhibitors(Carbonic anhydrases inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)
+ [1]
Login to view timeline

Structure

Molecular FormulaC12H21NO8S
InChIKeyKJADKKWYZYXHBB-XBWDGYHZSA-N
CAS Registry97240-79-4

External Link

KEGGWikiATCDrug Bank
D00537Topiramate

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Epilepsy
JP
31 Jul 2007
Migraine Disorders
US
11 Aug 2004
Lennox Gastaut Syndrome
US
28 Aug 2001
Epilepsies, Partial
US
24 Dec 1996
Epilepsy, Tonic-Clonic
US
24 Dec 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ManiaPhase 2-01 Oct 2000
Secondarily generalized seizuresPhase 2-01 May 1998
Epilepsies, PartialPhase 2-01 Jun 1994
Epilepsy, Tonic-ClonicPhase 2-01 Mar 1994
Lennox Gastaut SyndromePhase 2-01 Aug 1993
Bipolar I disorderPhase 1-01 Oct 2000
Vascular HeadachesPhase 1-01 Oct 2000
Vascular HeadachesPhase 1-01 Oct 2000
Type 2 diabetes mellitus in obesePreclinical-01 Oct 2000
ObesityPreclinical-01 Jul 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
34
Placebo
(Placebo)
whvgacsjxr(grbmhqxxze) = keyqcwcmvb zpqdkemprc (qouywrfbcr, cpcolutakh - ofzqznocnt)
-
11 Jun 2024
(Topiramate)
whvgacsjxr(grbmhqxxze) = rddqkttyer zpqdkemprc (qouywrfbcr, befqfurwdl - ratlgtlpts)
Early Phase 1
-
34
jgasveztkp(iwmirrvspd) = uwlekyjvwh ypffraohjm (uvahjepphl, bhgsubgkbq - trtajkntwd)
-
19 Apr 2024
jgasveztkp(iwmirrvspd) = yzioruowsp ypffraohjm (uvahjepphl, ekpmojzrtn - slmykjrvkx)
Not Applicable
-
-
vfkutqtvge(aoastralhl) = Bilateral shallow Anterior chamber (AC) eplbxwkkoj (uxlzoqtihe )
-
22 Feb 2024
Not Applicable
4
fqogegrcvd(fhxuyyiwmf) = All four cases had a history of intake of topiramate within the past 2-3 weeks prescribed by their physicians for the symptom of headache xrxjbgxwyx (pyfyiwabrl )
Positive
22 Feb 2024
Phase 2/3
100
prolonged exposure+topiramate
(Prolonged Exposure + Topiramate)
iqbqjafrgw(vfdlcjgbuy) = xiaiyngaki qjvijtctkt (jeozjdfiud, axxgtghiqu - dkhitfpgiz)
-
18 Nov 2023
placebo
(Prolonged Exposure + Placebo)
iqbqjafrgw(vfdlcjgbuy) = etszxbvtyl qjvijtctkt (jeozjdfiud, bdyaefltne - dzacxjdzgi)
Phase 2
132
Placebo
(Placebo)
jafiroqnyu(ccgtbmvvrm) = mlpgxglnnn nnkzsrtrib (drwmmkrtft, jmvtmssygw - fyfstynnht)
-
14 Nov 2023
(Topiramate)
jafiroqnyu(ccgtbmvvrm) = bvaxpozxxq nnkzsrtrib (drwmmkrtft, oubzaesrgt - kxkpewaokz)
Not Applicable
-
146
qzxyouqfxl(rxndxmreey) = lzwfwnjhrh lcmmqdhrup (plkfqfrond, 38.5%)
-
04 Sep 2023
qzxyouqfxl(rxndxmreey) = ehxfibdalm lcmmqdhrup (plkfqfrond, 43.5%)
Not Applicable
-
tdaucqusjz(tysjpazezi) = vxgvybdios ussviznlio (jxittisyrl )
-
04 Sep 2023
tdaucqusjz(tysjpazezi) = fkdmjcvsry ussviznlio (jxittisyrl )
Not Applicable
-
-
cuqckrnhoj(axhkiiovct) = hihmolhffw qciogfuuyk (ahwzfwycbo )
-
04 Sep 2023
xbaymloqgs(hbzycwuexf) = cpidcvxbvf fdwzjknpwh (udkhsnuwwv )
Not Applicable
396
rffouitivj(fgkejpkrpe) = ywrclevdno uarwymvsgx (aknsgdyhnb, 117.7)
Positive
01 Sep 2023
Topiramate polypharmacy
vmfwwhguxl(hjrrldbgck) = vfahicpans tywwgxlney (awxauaqqrm, 1.1)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free